The Combined Role of EN2, CD73 and KI67 in Predicting Recurrence and Progression of Non-muscle Invasive Bladder Cancer

Yomna A. Zamzam^1, , Aymen M. El-Saka¹, Ahmed M. El-Saka² and Hassan El-Tatawy²

¹Department of Pathology, Faculty of Medicine, Tanta University, Egypt

²Department of Urology, Faculty of Medicine, Tanta University, Egypt

Cite this paper:
Yomna A. Zamzam, Aymen M. El-Saka, Ahmed M. El-Saka and Hassan El-Tatawy. The Combined Role of EN2, CD73 and KI67 in Predicting Recurrence and Progression of Non-muscle Invasive Bladder Cancer. Journal of Cancer Research and Treatment. 2017; 5(3):92-99. doi: 10.12691/jcrt-5-3-4

Abstract

Objectives: The survival rate for the most of patients with non- muscle invasive bladder cancer (NMIBC) is favorable; however, the rates of recurrence and progression to muscle invasive bladder cancer (MIBC) are the major principles of long- term outcome. There is an essential need to find a panel of markers to predict tumor recurrence and progression to be used in regular clinical practice and treat the disease appropriately. Therefore, we investigated in this study, the immunohistochemical expression of EN2, CD73, p63 and Ki-67 in NMIBC in order to evaluate the ability of this panel of markers to predict tumor recurrence and progression. Methods: In all, 122 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology and Pathology Department from January 2014 to December 2016, were included in the study. Paraffin-embedded specimens were obtained by transurethral resection of the bladder tumors. After grading and staging of the sections stained with haematoxylin and eosin, they were evaluated using EN2, CD73 p63 and KI67 immunohistochemical staining before and after immunotherapy with bacille Calmette-Guerin (BCG), and patients were followed up for 3 years. Results: High CD73 expression is significantly associated with lower stage (p= 0.01) and lower grade (p= 0.02). There was no significant relationship between EN2, p63 and KI67 expression and tumor staging or grading. There was a significant relation between EN2, Ki67 positivity and CD73 negativity with recurrence, progression and death of the studied cases. Conclusions: Patients with TCC who are selected for BCG treatment should preferably be positively immunoreactive for CD73 but negative for both EN2 and Ki67. These patients are likely to be less susceptible to recurrence and/or progression after BCG adjuvant therapy. On the other hand different immunological profile necessitates closer follow up for early detection of tumor recurrence and progression.

Keywords:
Non-muscle invasive bladder cancer Transitional cell carcinoma bacille Calmette–Guerin - EN2 CD73 Ki67

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Hall MC, Chang SS, Dalbagni G, Seigne JD, Skinner EC. The Bladder Cancer Clinical Guideline Update Panel. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis). J Urol 2007; 2007(178): 2314-30, Update.
[2]	Hegazy R, kamel M, Salem EA, Salem NA, Fawzy A, Sakr A, et al. The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette–Guerin. Arab Journal of Urolog. 2015; 13(3), 225-230.
[3]	Feng C, Wang L, Ding G, Ding Q, Zhou Z, Jiang H, et al. Predictive value of clinicopathological markers for the metachronous bladder cancer and prognosis of upper tract urothelial carcinoma. Sci Rep. 2014; 4: 4015.
[4]	Stenzl A, Hennenlotter J, Schilling D. Can we still afford bladder cancer? Curr Opin Urol 2008; 18:488-492.
[5]	Wang L, Feng C, Ding G, Ding Q, Zhou Z, Jiang H, et al. Ki67 and TP53 expressions predict recurrence of non-muscle invasive bladder cancer. Tumour Biol. 2014; 35: 2989-2995.
[6]	Charfia S, Khabir A, Mnifa H, Ellouzea S, Mhirib M, Sellamia T. Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression. J Microsc Ultrastruct. 2013; 1: 17-21.
[7]	Wang L, Zhou M, Feng C, Gao P, Ding G, Zhou Z, et al. Prognostic value of Ki67 and p63 expressions in bladder cancer patients who underwent radical cystectomy. Int Urol Nephrol. 2016 Apr; 48(4): 495-501.
[8]	Charfia S, Khabir A, Mnifa H, Ellouzea S, Mhirib M, Sellamia T. Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression. J Microsc Ultrastruct. 2013; 1: 17-21.
[9]	Li Y, Liu H, Lai C, Su Z, Heng B, Gao S. Repression of engrailed 2 inhibits the proliferation and invasion of human bladder cancer in vitro and in vivo. Oncol Rep. 2015 May; 33(5): 2319-30.
[10]	Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, et al. Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. Eur J Cancer. 2013 Jun; 49(9): 2214-22.
[11]	Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, et al. Engrailed-2(EN2): a highly specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res. 2011; 17: 1090-1098.
[12]	REN ZH, YUAN YX, JI T, ZHANG CP. CD73 as a novel marker for poor prognosis of oral squamous cell carcinoma. Oncology Letters. 2016; 12 (1): 556-562.
[13]	Zhang B, CD73 promotes tumor growth and metastasis. OncoImmunology. 2012; vol. 1, no. 1, pp. 67-70.
[14]	Wang L, Tang S, Wang Y, Xu S, Yu J, Zhi X, et al. Ecto-5′- nucleotidase (CD73) promotes tumor angiogenesis. Clin Exp Metastasis. 2013; 30: 671-680.
[15]	Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012; 106: 130-137.
[16]	Wettstein MS, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P, et al. CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. Dis Markers. 2015: 785461
[17]	Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002; 161: 1199-1206.
[18]	Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003; 9: 5501-5507.
[19]	Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee I, et al. p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers. PLoS ONE. 2012; 7(1).
[20]	Shariat SF, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B, et al. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int. 2014; 113: 70-76.
[21]	Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC; 2004.
[22]	Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th ed. Weinheim: Wiley; 2009.
[23]	Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016 Oct;196(4):1021-9
[24]	Oh HK, Sin JI, Choi J, Park SH, Lee TS, Choi YS. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. Journal of Gynecologic Oncology. 2012; vol. 23, no. 4, pp. 274-281.
[25]	Supernat A, Markiewicz A, Welnicka-Jaskiewicz M. CD73 expression as a potential marker of good prognosis in breast carcinoma. Applied Immunohistochemistry & Molecular Morphology. 2012; vol. 20, no. 2, pp. 103-107.
[26]	Liu N, Fang XD, Vadis Q. CD73 as a novel prognostic biomarker for human colorectal cancer,” Journal of Surgical Oncology. 2012; vol. 106, no. 7, pp. 918-919.
[27]	Yang Q, Du J, Zu L. Overexpression of CD73 in prostate cancer is associated with lymph node metastasis,” Pathology and Oncology Research. 2013; vol. 19, no. 4, pp. 811-814.
[28]	Lu XX, Chen YT, Feng B, Mao XM, Yu B, Chu XY. Expression and clinical significance of CD73 and hypoxia inducible factor-1 in gastric carcinoma. World Journal of Gastroenterology. 2013; vol.19, no. 12, pp. 1912-1918.
[29]	Gaya JM, López-Martínez JM, Karni-Schmidt O, “ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer,” Journal of Urology. 2015; vol. 193, no. 4, pp. 1144-1150.